Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients

Medicine
Aviad ZickHanoch Goldshmidt

Abstract

Molecular portraits of numerous tumors have flooded oncologists with vast amounts of data. In parallel, effective inhibitors of central pathways have shown great clinical benefit. Together, this promises potential clinical benefits to otherwise end-stage cancer patients. Here, we report a clinical service offering mutation detection of archived samples using the ion Ampliseq cancer panel coupled with clinical consultation.A multidisciplinary think tank consisting of oncologists, molecular-biologists, genetic counselors, and pathologists discussed 67 heavily pretreated, advanced cancer patient cases, taking into account mutations identified using ion Ampliseq cancer panel, medical history, and relevant literature.The team generated a treatment plan, targeting specific mutations, for 41 out of 64 cases. Three patients died before results were available. For 32 patients, the treating oncologists chose not to include the panel recommendation in the treatment plan for various reasons. Nine patients were treated as recommended by the panel, 5 with clinical benefit, and 4 with disease progression.This study suggests that routine use of massive parallel tumor sequencing is feasible and can judiciously affect treatment decisions when co...Continue Reading

References

Jan 25, 1996·The New England Journal of Medicine·S W LambertsL J Hofland
Jun 18, 2002·Nature·Helen DaviesP Andrew Futreal
Aug 16, 2002·The New England Journal of Medicine·George D DemetriHeikki Joensuu
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Jul 15, 2005·The New England Journal of Medicine·Frances A ShepherdUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Dec 29, 2006·The New England Journal of Medicine·Charles E GeyerDavid Cameron
Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
Jan 12, 2007·The New England Journal of Medicine·Bernard EscudierUNKNOWN TARGET Study Group
May 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yutaka SuehiroStanley R Hamilton
Sep 6, 2008·Nature·UNKNOWN Cancer Genome Atlas Research Network
Oct 24, 2008·The New England Journal of Medicine·Christos S KarapetisJohn R Zalcberg
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Sep 3, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Soundararajan KrishnaswamyRavi Salgia
Sep 4, 2009·The New England Journal of Medicine·Daniel D Von HoffJennifer A Low
Sep 17, 2010·The New England Journal of Medicine·Srdan VerstovsekAyalew Tefferi
Oct 6, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel D Von HoffRobert Penny
Oct 19, 2010·Nucleic Acids Research·Simon A ForbesP Andrew Futreal
Oct 29, 2010·The New England Journal of Medicine·James E ButrynskiGeoffrey I Shapiro
Nov 5, 2010·The New England Journal of Medicine·Darcy A KruegerDavid Neal Franz
Jan 21, 2011·Indian Journal of Cancer·K M GalalAbdel Monem M Mourad
Feb 11, 2011·The New England Journal of Medicine·James C YaoUNKNOWN RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group
Mar 4, 2011·The New England Journal of Medicine·Deborah A ZarinNicholas C Ide
Jun 7, 2011·The New England Journal of Medicine·Paul B ChapmanUNKNOWN BRIM-3 Study Group
Jul 2, 2011·Nature·UNKNOWN Cancer Genome Atlas Research Network
Nov 4, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·John M KirkwoodReinhard Dummer
Nov 10, 2011·Investigational New Drugs·Jin Hyun ChoJeeyun Lee
Dec 14, 2011·The New England Journal of Medicine·José BaselgaUNKNOWN CLEOPATRA Study Group
Dec 14, 2011·The New England Journal of Medicine·José BaselgaGabriel N Hortobagyi
Jan 5, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kristin BergethonA John Iafrate
Feb 14, 2012·Nature Medicine·Doron LipsonPhilip J Stephens
Apr 21, 2012·Briefings in Bioinformatics·Helga ThorvaldsdóttirJill P Mesirov
Jun 6, 2012·The New England Journal of Medicine·Keith T FlahertyUNKNOWN METRIC Study Group
Jun 23, 2012·Nature·Catherine S GrassoScott A Tomlins
Jul 17, 2012·Cancer Discovery·Kimberly Brown DahlmanWilliam Pao

❮ Previous
Next ❯

Methods Mentioned

BETA
chip
biopsies

Software Mentioned

Ion Variant

Related Concepts

Related Feeds

Cancer Sequencing

Several sequencing approaches are employed to understand and examine tumor development and progression. These include whole genome as well as RNA sequencing. Here is the latest research on cancer sequencing.